Alta Sciences

FEBRUARY 8, 2024

Utilizing 10 state-of-the-art simulators available in-house at our Montréal clinical facility (with the capacity for more than 20), we are equipped to measure a range of studies; from impairment in cognition and comparing compounds to assessing the impact on new formulations have on impairment.

Clinical Trials 52

Clinical Trials Trials Clinical Pharmacology Clinical Development 52

The Pharma Data

NOVEMBER 1, 2020

Dr Nurbhai has more than 25 years of experience and a strong track record in the strategic and operational leadership of all phases of clinical research and development at companies across Europe and the US. He joins Mission from VHsquared, where he held the position of CMO since 2014.

Clinical Pharmacology 52

Clinical Pharmacology Small Molecule Clinical Research Science 52

New Drug Approvals

SEPTEMBER 13, 2024

. “Blockade of kappa-opioid receptors amplifies microglia-mediated inflammatory responses” Pharmacology, Biochemistry, and Behavior. February 2014). September 2014). October 2014). Jump up to: a b Urbano M, Guerrero M, Rosen H, Roberts E (May 2014). 212 : 173301. doi : 10.1016/j.pbb.2021.173301.

Treatment 62

Treatment Clinical Trials Pharmacokinetics Pharmaceuticals 62

Metabolite Tales Blog

JULY 5, 2023

20 (March 20, 2014). link] [6] PHARMACOLOGY/TOXICOLOGY NDA REVIEW AND EVALUATION Study NC219 [link] [7] Acute Liver Injury due to Glecaprevir/Pibrentasvir in a Patient with Chronic Hepatitis C Virus Infection without Cirrhosis. link] [9] PHARMACOLOGY/TOXICOLOGY NDA REVIEW AND EVALUATION.

Drugs 52

Drugs Metabolic Stability FDA Approval Treatment 52

Metabolite Tales Blog

JULY 5, 2023

20 (March 20, 2014). link] [6] PHARMACOLOGY/TOXICOLOGY NDA REVIEW AND EVALUATION Study NC219 [link] [7] Acute Liver Injury due to Glecaprevir/Pibrentasvir in a Patient with Chronic Hepatitis C Virus Infection without Cirrhosis. link] [9] PHARMACOLOGY/TOXICOLOGY NDA REVIEW AND EVALUATION.

Metabolic Stability 52

Metabolic Stability Drugs FDA Approval Treatment 52

Agency IQ

SEPTEMBER 29, 2023

As part of the classification process, we are required to discuss the potential classification before an advisory committee and seek the committee’s recommendation on classification, which took place in October 2014.

FDA 40

FDA Science Regulations Production 40

Agency IQ

JUNE 16, 2023

As part of the classification process, we are required to discuss the potential classification before an advisory committee and seek the committee’s recommendation on classification, which took place in October 2014.

Regulations 40

Regulations FDA Science Production 40